for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ProPhase Labs Inc

PRPH.OQ

Latest Trade

1.87USD

Change

0.02(+1.08%)

Volume

485

Today's Range

1.78

 - 

1.87

52 Week Range

1.72

 - 

3.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.85
Open
1.78
Volume
485
3M AVG Volume
0.17
Today's High
1.87
Today's Low
1.78
52 Week High
3.99
52 Week Low
1.72
Shares Out (MIL)
11.56
Market Cap (MIL)
21.63
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

ProPhase Labs Reports Quarterly Loss Per Share Of $0.11

Prophase Labs Reports Quarterly Loss Per Share $0.09

Prophase Announces Change In Tax Treatment Of 2018 Dividends

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ProPhase Labs Inc

ProPhase Labs, Inc. manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company's products include TK Supplements and ORXx Complete. TK Supplements consists of LEGENDZ XL, a male sexual enhancement; TRIPLE EDGE XL, a daily energy and stamina booster, and SUPER PROSTAFLOW plus, a supplement to support prostate and urinary health. The Company's OTC offerings include the ORXx cough/cold drops. Its consumer health customers include national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

Industry

Biotechnology & Drugs

Contact Info

621 N Shady Retreat Rd

+1.215.3450919

http://www.prophaselabs.com/

Executive Leadership

Ted William Karkus

Chairman of the Board, Chief Executive Officer

Monica L. Brady

Chief Financial Officer

Jason M. Barr

Director

Louis Gleckel

Independent Director

James T. McCubbin

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
2.06
Price To Book (MRQ)
1.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-20.38
Return on Equity (TTM)
-19.01

Latest News

BRIEF-Prophase Labs Announces Special Cash Dividend

* BOARD OF DIRECTORS HAS DECLARED A SPECIAL CASH DIVIDEND IN AMOUNT OF $1.00 PER SHARE ON ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Prophase Labs Announces New Compensatory Arrangement With CEO And Termination Of Stockholder Rights Plan

* PROPHASE LABS, INC. ANNOUNCES NEW COMPENSATORY ARRANGEMENT WITH CHIEF EXECUTIVE OFFICER AND TERMINATION OF STOCKHOLDER RIGHTS PLAN

BRIEF-ProPhase Labs quarterly loss per share $0.05 from continuing operations

* ProPhase Labs reports financial results for the three months and nine months ended September 30, 2017

BRIEF-Prophase Labs intends to commence tender offer to repurchase up to 1.7 mln shares

* Prophase Labs, Inc. announces intention to commence tender offer to repurchase up to 1,700,000 shares of its common stock

BRIEF-BML Investment Partners reports 5.05 pct passive stake in ProPhase Labs

* BML Investment Partners Lp reports 5.05 percent passive stake in ProPhase Labs Inc as of September 29 - SEC filing Source: (http://bit.ly/2yjT6PY) Further company coverage:

BRIEF-ProPhase Labs, Inc. announces final results of its tender offer

* ProPhase Labs, Inc. Announces final results of its tender offer

BRIEF-Prophase labs says ‍to purchase up to 4 mln shares of its common stock at a price of $2.30 per share​

* Prophase Labs Inc - to purchase up to 4 million shares of its common stock at a price of $2.30 per share Source text for Eikon: Further company coverage:

BRIEF-ProPhase Labs CFO Robert Cuddihy to resign

* Says on August 22, CFO Robert V. Cuddihy Jr., notified company of his intention to resign - SEC filing

BRIEF-Prophase Labs Inc qtrly sales $1.9 million

* Prophase Labs reports financial results for the three months and six months ended June 30, 2017

BRIEF-ProPhase provides shareholder update

* ProPhase Labs Inc- Company received net proceeds from sale of cold-eeze(®) of approximately $39.3 million after certain deductions

BRIEF-Prophase labs announces agreement to sell cold-eeze(r) brand

* Prophase labs announces agreement to sell cold-eeze(r) brand

BRIEF-Prophase Labs files for non-timely 10-Q

* Prophase labs-was unable to file form 10-q for september quarter because of technical connectivity difficulties between filing server and edgar server

BRIEF-ProPhase Labs quarterly earnings per share $0.01

* Prophase labs reports financial results for the three months and nine months ended september 30, 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up